Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Oncotype DX DCIS breast cancer test (Genomic Health Inc.) Lansdale: HAYES, Inc. Genetic Testing Publication. 2016 Authors' objectives Ductal carcinoma in situ (DCIS), commonly referred to as stage 0 breast cancer, is defined as neoplastic proliferation of epithelial cells that are confined to the mammary ductal-lobular system. Advancements in routine screening mammography have seen a substantial increase in the number of DCIS cases diagnosed each year, yet the prognosis for a woman diagnosed with DCIS is not well defined. Current recommended treatment guidelines for DCIS include lumpectomy plus radiation, total mastectomy, or lumpectomy without radiation. Postsurgical treatment guidelines include the use of endocrine therapy and counseling for risk reduction, and physical examination/mammography every 6 to 12 months for 5 years. This uncertainty in prognosis results in inadequate treatment with elevated risk for recurrence of DCIS or other invasive breast
carcinoma for some patients, and unnecessary treatment with risk of serious side effects for others; therefore, prognostic tools that reliably differentiate patients at high risk of recurrence from those at lower risk would be beneficial. The focus of this report is to assess the evidence that supports the use of the Oncotype DX DCIS assay (Genomic Health Inc.). Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Humans; Receptors, Estrogen Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32017000085 Date abstract record published 06/01/2017 |